All (n = 669) | Previous CVD (n = 143) | No previous CVD (n = 526) | P-value | |
---|---|---|---|---|
Female, n (%) | 299 (45) | 60 (42) | 239 (45) | 0.46 |
Age, years | 55 ± 13 | 61 ± 9 | 53 ± 13 | < 0.01 |
Diabetes duration, years | 35 [24–44] | 42 [34–49] | 33 [19–42] | < 0.01 |
BMI, kg/m2 | 26 ± 6 | 25 ± 4 | 25 ± 6 | 0.97 |
Systolic blood pressure (mmHg) | 132 ± 18 | 135 ± 20 | 131 ± 17 | 0.01 |
Diastolic blood pressure (mmHg) | 74 ± 9 | 71 ± 9 | 75 ± 9 | < 0.01 |
Mean arterial pressure (mmHg) | 93 ± 10 | 92 ± 11 | 94 ± 10 | 0.15 |
HbA1c, % (mmol/mol) | 8.0 ± 1.2 (64 ± 13) | 8.2 ± 1.2 (67 ± 13) | 8.0 ± 1.2 (64 ± 13) | 0.02 |
Total cholesterol, mmol/l | 4.7 ± 0.9 | 4.6 ± 0.9 | 4.7 ± 0.9 | 0.47 |
LDL cholesterol, mmol/l | 2.5 ± 0.8 | 2.3 ± 0.7 | 2.5 ± 0.8 | 0.01 |
HDL cholesterol, mmol/l | 1.7 ± 0.5 | 1.7 ± 0.5 | 1.7 ± 0.5 | 0.93 |
Triglycerides, mmol/l | 1.0 [0.7–1.3] | 1.0 [0.8–1.6] | 0.9 [0.7–1.3] | < 0.01 |
eGFR, ml/min/1.73 m2 | 81 ± 26 | 67 ± 25 | 85 ± 24 | < 0.01 |
UAER, mg/24-h | 18 [8–64] | 34 [11–124] | 15 [8–52] | < 0.01 |
Smokers, n (%) | 139 (21) | 27 (19) | 112 (21) | 0.53 |
Antihypertensives, n (%) | 481 (72) | 135 (94) | 346 (66) | < 0.01 |
Statins, n, % | 401 (60) | 120 (84) | 281 (54) | < 0.01 |
Aspirin or Clopidogrel n (%) | 352 (53) | 125 (88) | 227 (64) | < 0.01 |
Follow-up | ||||
Any CVE*, n (%) | 95 (14) | 55 (38) | 40 (8) | < 0.01 |
CV mortality, n (%) | 11 (2) | 8 (6) | 3 (1) | < 0.01 |
Coronary artery disease†, n (%) | 45 (7) | 27 (19) | 18 (3) | < 0.01 |
Non-fatal stroke, n (%) | 23 (3) | 12 (8) | 11 (2) | < 0.01 |
Peripheral arterial interventions, n (%) | 35 (5) | 21 (15) | 14 (3) | < 0.01 |